This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andrei, G.
Right arrow Articles by De Clercq, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andrei, G.
Right arrow Articles by De Clercq, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Mar 1997, 587-593, Vol 41, No. 3
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Activities of various compounds against murine and primate polyomaviruses

G Andrei, R Snoeck, M Vandeputte and E De Clercq
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.

Polyomavirus infections in humans are due to BK virus (BKV) and JC virus (JCV). Diseases associated with human polyomaviruses occur mostly in immunocompromised adults, e.g., progressive multifocal leukoencephalopathy (PML), caused by JCV, in AIDS patients and hemorrhagic cystitis and uretral stenosis, caused by BKV, in transplant recipients. No therapy is available for these diseases, which necessitates the development of chemical entities that are active against polyomaviruses. Several antiviral compounds were evaluated to determine their effects on the in vitro replication of mouse polyomavirus and the primate viruses simian virus 40 (SV40), SV40 PML- 1, and SV40 PML-2. The activity of the different compounds was assessed by a cytopathic effect reduction assay and confirmed in a virus yield assay. Cidofovir [HPMPC; (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl)cytosine] and its cyclic counterpart emerged as the most selective antipolyomavirus agents. The 50% inhibitory concentrations for HPMPC were in the range of 4 to 7 micrograms/ml, and its selectivity index varied from 11 to 20 for mouse polyomavirus and from 23 to 33 for SV40 strains in confluent cell monolayers. Cell cytotoxicity was up to 15-fold greater in growing cells. Other acyclic nucleoside phosphonates (i.e., HPMPA; [(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] and PMEG [9-(2-phosphonylmethoxyethyl)- guanine]) also showed some activity but had low selectivity. None of the other drugs tested against these animal viruses (i.e., acyclovir, ganciclovir, brivudine, ribavirin, foscarnet, and cytarabine) showed significant activity. Thus, HPMPC deserves further evaluation as a candidate drug for polyomavirus infections in the immunocompromised host.


This article has been cited by other articles:

  • Brickelmaier, M., Lugovskoy, A., Kartikeyan, R., Reviriego-Mendoza, M. M., Allaire, N., Simon, K., Frisque, R. J., Gorelik, L. (2009). Identification and Characterization of Mefloquine Efficacy against JC Virus In Vitro. Antimicrob. Agents Chemother. 53: 1840-1849 [Abstract] [Full Text]  
  • Wu, S.-W., Chang, H.-R., Lian, J.-D. (2009). The effect of low-dose cidofovir on the long-term outcome of polyomavirus-associated nephropathy in renal transplant recipients. Nephrol Dial Transplant 24: 1034-1038 [Abstract] [Full Text]  
  • Randhawa, P., Zemlicka, J., Sauerbrei, A., Meier, C., Hostetler, K. Y., Beadle, J. R., Farasati, N. A., Huang, Y., Bradley, M. (2008). Anti-BK Virus Activity of Nucleoside Analogs. Antimicrob. Agents Chemother. 52: 1519-1521 [Abstract] [Full Text]  
  • Bohl, D. L., Brennan, D. C. (2007). BK Virus Nephropathy and Kidney Transplantation. CJASN 2: S36-S46 [Abstract] [Full Text]  
  • Lebeau, I., Andrei, G., Krecmerova, M., De Clercq, E., Holy, A., Snoeck, R. (2007). Inhibitory Activities of Three Classes of Acyclic Nucleoside Phosphonates against Murine Polyomavirus and Primate Simian Virus 40 Strains. Antimicrob. Agents Chemother. 51: 2268-2273 [Abstract] [Full Text]  
  • Owczarczyk, K., Hilker, R., Brunn, A., Hallek, M., Rubbert, A. (2007). Progressive multifocal leucoencephalopathy in a patient with sarcoidosis--successful treatment with cidofovir and mirtazapine. Rheumatology (Oxford) 46: 888-890 [Full Text]  
  • Blanckaert, K., De Vriese, A. S. (2006). Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients. Nephrol Dial Transplant 21: 3364-3367 [Full Text]  
  • Berger, J R (2006). Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 65: iii48-iii53 [Abstract] [Full Text]  
  • Lebeau, I., Andrei, G., Dal Pozzo, F., Beadle, J. R., Hostetler, K. Y., De Clercq, E., van den Oord, J., Snoeck, R. (2006). Activities of Alkoxyalkyl Esters of Cidofovir (CDV), Cyclic CDV, and (S)-9-(3-Hydroxy-2-Phosphonylmethoxypropyl)Adenine against Orthopoxviruses in Cell Monolayers and in Organotypic Cultures.. Antimicrob. Agents Chemother. 50: 2525-2529 [Abstract] [Full Text]  
  • Randhawa, P., Farasati, N. A., Shapiro, R., Hostetler, K. Y. (2006). Ether Lipid Ester Derivatives of Cidofovir Inhibit Polyomavirus BK Replication In Vitro.. Antimicrob. Agents Chemother. 50: 1564-1566 [Abstract] [Full Text]  
  • Viallard, J-F, Ellie, E, Lazaro, E, Lafon, M-E, Pellegrin, J-L (2005). JC virus meningitis in a patient with systemic lupus erythematosus. Lupus 14: 964-966 [Abstract]  
  • Zaragoza, C., Li, R.-m., Fahle, G. A., Fischer, S. H., Raffeld, M., Lewis, A. M. Jr., Kopp, J. B. (2005). Squirrel Monkeys Support Replication of BK Virus More Efficiently than Simian Virus 40: an Animal Model for Human BK Virus Infection. J. Virol. 79: 1320-1326 [Abstract] [Full Text]  
  • Tong, C. Y. W., Hilton, R., MacMahon, E. M. E., Brown, L., Pantelidis, P., Chrystie, I. L., Kidd, I. M., Tungekar, M. F., Pattison, J. M. (2004). Monitoring the progress of BK virus associated nephropathy in renal transplant recipients. Nephrol Dial Transplant 19: 2598-2605 [Abstract] [Full Text]  
  • De Clercq, E. (2003). Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections. Clin. Microbiol. Rev. 16: 569-596 [Abstract] [Full Text]  
  • Mengel, M., Marwedel, M., Radermacher, J., Eden, G., Schwarz, A., Haller, H., Kreipe, H. (2003). Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant 18: 1190-1196 [Abstract] [Full Text]  
  • Keller, L. S., Peh, C. A., Nolan, J., Bannister, K. M., Clarkson, A. R., Faull, R. J. (2003). BK transplant nephropathy successfully treated with cidofovir. Nephrol Dial Transplant 18: 1013-1014 [Full Text]  
  • Ramos, E., Drachenberg, C. B., Papadimitriou, J. C., Hamze, O., Fink, J. C., Klassen, D. K., Drachenberg, R. C., Wiland, A., Wali, R., Cangro, C. B., Schweitzer, E., Bartlett, S. T., Weir, M. R. (2002). Clinical Course of Polyoma Virus Nephropathy in 67 Renal Transplant Patients. J. Am. Soc. Nephrol. 13: 2145-2151 [Abstract] [Full Text]  
  • Randhawa, P. S., Demetris, A. J. (2000). Nephropathy Due to Polyomavirus Type BK. NEJM 342: 1361-1363 [Full Text]  
  • Hahn, J. S., Harris, B. T., Gutierrez, K., Sandborg, C. (1998). Progressive Multifocal Leukoencephalopathy in a 15-Year-Old Boy With Scleroderma and Secondary Amyloidosis. Pediatrics 102: 1475-1479 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»